Onconetix, Inc. Net Fee Amt
Onconetix, Inc. (ONCO) had Net Fee Amt of $11.05 thousand as of 2026-08-11, per its S-1 filed 2026-08-12.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-12
- 2026-08-11: Net Fee Amt $11.05K.
- 2026-05-06: Net Fee Amt $2.89K.
- 2026-04-28: Net Fee Amt $2.32K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-11 | $11.05K S-1 · filed 2026-08-12 |
| 2026-05-06 | $2.89K POS AM · filed 2026-05-07 |
| 2026-04-28 | $2.32K S-1 · filed 2026-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |